Key Points
- Director Patrick Heron purchased 131,425 shares at $68.48 on Jan. 23 (~$9.0M), raising his stake ~40% to 459,010 shares valued at about $31.4M, a strong insider vote of confidence.
- C-suite insiders sold stock the same day — CEO Christopher Peetz sold 6,831 shares (~$657K) and other senior execs sold smaller amounts — which may prompt investor concern about near‑term insider liquidity despite the director buy.
- Market and operational catalysts are largely positive: HC Wainwright upgraded MIRM to Buy with a $130 target, Mirum completed the Bluejay acquisition, and recent revenue beat estimates (+47% YoY), though EPS and margins remain negative and the consensus is a "Moderate Buy."
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Get Free Report) Director Patrick Heron acquired 131,425 shares of the company's stock in a transaction that occurred on Friday, January 23rd. The stock was purchased at an average cost of $68.48 per share, for a total transaction of $8,999,984.00. Following the acquisition, the director owned 459,010 shares in the company, valued at approximately $31,433,004.80. This trade represents a 40.12% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through this link.
Mirum Pharmaceuticals Trading Up 2.4%
Mirum Pharmaceuticals stock opened at $99.27 on Wednesday. Mirum Pharmaceuticals, Inc. has a 52-week low of $36.88 and a 52-week high of $99.44. The company has a quick ratio of 3.16, a current ratio of 3.31 and a debt-to-equity ratio of 1.06. The firm has a market capitalization of $5.10 billion, a price-to-earnings ratio of -115.43 and a beta of 0.48. The firm has a 50-day moving average price of $78.36 and a two-hundred day moving average price of $71.54.
Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last announced its quarterly earnings results on Tuesday, November 4th. The company reported $0.05 EPS for the quarter, beating the consensus estimate of ($0.10) by $0.15. The company had revenue of $133.01 million for the quarter, compared to analyst estimates of $130.11 million. Mirum Pharmaceuticals had a negative net margin of 8.78% and a negative return on equity of 16.47%. Mirum Pharmaceuticals's revenue was up 47.1% compared to the same quarter last year. During the same quarter last year, the business earned ($0.30) earnings per share. Sell-side analysts expect that Mirum Pharmaceuticals, Inc. will post -1.43 earnings per share for the current year.
Key Headlines Impacting Mirum Pharmaceuticals
Here are the key news stories impacting Mirum Pharmaceuticals this week:
- Positive Sentiment: Director Patrick J. Heron purchased 131,425 shares at $68.48 (≈$9.0M), increasing his stake by ~40%, a strong insider vote of confidence in the company and its valuation. Director Form 4
- Positive Sentiment: HC Wainwright upgraded MIRM to Buy, raised the price target from $102 to $130 and published an aggressive FY2030 EPS projection ($6.16), signaling bullish long‑term expectations from a coverage analyst and supporting higher share valuations. HC Wainwright Coverage
- Positive Sentiment: Mirum completed the acquisition of Bluejay Therapeutics, expanding its rare-disease pipeline and global footprint—an acquisition likely viewed as strategically accretive and supportive of future revenue growth. Acquisition Announcement
- Positive Sentiment: Coverage and market reaction have pushed MIRM to a new 52‑week high following the analyst upgrade, which can attract momentum/technical buyers. 52‑Week High Article
- Negative Sentiment: CEO Christopher Peetz sold 6,831 shares at ~$96.19 (~$657K), reducing his stake by ~3.9%. CEO Form 4
- Negative Sentiment: Other senior exec sales the same day: COO Peter Radovich (3,143 shares), CFO Eric Bjerkholt (1,053 shares) and SVP Jolanda Howe (842 shares) — these reduce insider holdings and may concern some investors about near‑term insider liquidity. COO Form 4 CFO Form 4 SVP Form 4
Analyst Ratings Changes
Several research analysts have recently issued reports on the company. Leerink Partners set a $100.00 price target on Mirum Pharmaceuticals in a research note on Wednesday, December 10th. HC Wainwright increased their target price on shares of Mirum Pharmaceuticals from $102.00 to $130.00 and gave the company a "buy" rating in a research report on Monday. Citigroup restated an "outperform" rating on shares of Mirum Pharmaceuticals in a research report on Friday, December 19th. TD Cowen reaffirmed a "buy" rating on shares of Mirum Pharmaceuticals in a research note on Monday, January 12th. Finally, Citizens Jmp increased their price objective on shares of Mirum Pharmaceuticals from $95.00 to $140.00 and gave the company a "market outperform" rating in a report on Friday, December 19th. One research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $104.92.
Check Out Our Latest Stock Analysis on MIRM
Institutional Trading of Mirum Pharmaceuticals
A number of hedge funds and other institutional investors have recently made changes to their positions in MIRM. CWM LLC boosted its holdings in Mirum Pharmaceuticals by 30.8% during the third quarter. CWM LLC now owns 683 shares of the company's stock worth $50,000 after buying an additional 161 shares in the last quarter. Legal & General Group Plc increased its holdings in shares of Mirum Pharmaceuticals by 0.4% in the second quarter. Legal & General Group Plc now owns 43,010 shares of the company's stock valued at $2,189,000 after buying an additional 176 shares in the last quarter. MCF Advisors LLC lifted its position in shares of Mirum Pharmaceuticals by 76.4% during the 3rd quarter. MCF Advisors LLC now owns 427 shares of the company's stock valued at $31,000 after acquiring an additional 185 shares during the last quarter. Teacher Retirement System of Texas boosted its stake in shares of Mirum Pharmaceuticals by 2.2% during the 2nd quarter. Teacher Retirement System of Texas now owns 9,903 shares of the company's stock worth $504,000 after acquiring an additional 215 shares in the last quarter. Finally, Jones Financial Companies Lllp boosted its stake in shares of Mirum Pharmaceuticals by 34.0% during the 3rd quarter. Jones Financial Companies Lllp now owns 957 shares of the company's stock worth $70,000 after acquiring an additional 243 shares in the last quarter.
About Mirum Pharmaceuticals
(
Get Free Report)
Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company's primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.
Mirum's lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
